🇺🇸 FDA
Pipeline program

AXS-05

AXS-05-MDD-301

Phase 3 small_molecule completed

Quick answer

AXS-05 for Depression is a Phase 3 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Axsome Therapeutics
Indication
Depression
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials